S6 Ep35: Hurvitz Reviews Pivotal Data From 2021, Previews Year Ahead in HER2+ Metastatic Breast Cancer
S6 Ep34: Jain Talks Patient Management, Dosing, and Toxicity Mitigation With Frontline PARP Maintenance in Ovarian Cancer
S6 Ep28: Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
S6 Ep33: Cleveland Clinic Faculty Speak to Shifting Standards in Hematologic Malignancies
S6 Ep32: Simon Shares Steps Towards Bridging Clinical Trial Disparities in Cancer
S6 Ep31: Rare Cancers Report: Pediatric Neuroblastoma
S6 Ep30: Ramchandren Reviews the Rationale to Further Evaluate CLR 131 in Waldenström Macroglobulinemia
S6 Ep29: Sorting Through Sexism, Guilt, and Motherhood in Medicine
S6 Ep27: Wang Reflects on Ibrutinib’s Role and Emerging Research in MCL Management
S6 Ep26: Research Reflections: Coombs Provides Insight Into Key ASH Abstracts in CLL
S6 Ep25: Basu on Getting Ahead of the Shadow Curve of COVID-19 in Oncology
S6 Ep24: Meyer Characterizes Current Approaches to Diagnosing, Managing, and Studying Cardiac Angiosarcoma
S6 Ep23: Dietz Draws Attention to Gender Disparities in Breast Cancer
S6 Ep22: Gilbert on Gaining New Ground at Vanderbilt
S6 Ep21: Bardia on Sacituzumab Govitecan’s Current and Potential Future Position in TNBC
S6 Ep21: Gasparetto Talks Management Strategies for Belantamab Mafodotin–Related Ocular Toxicity in Myeloma
S6 Ep20: Phillips Reflects on Lessons Learned With BTK Inhibitors in MCL
S6 Ep19: Schwartzberg on Bringing Seminal Observations on AR From Bench to Bedside in ER+ Breast Cancer
S6 Ep18: Hochster Underscores Headway Made in Gastric/GEJ Cancers
S6 Ep17: Shah and Wang Share Insights Into Optimized CAR T-Cell Therapy in Hematologic Malignancies
S6 Ep16: Coombs Previews Anticipated ASH Abstracts in CLL
S6 Ep15: FDA Approval Insights: Adjuvant Pembrolizumab in RCC
S6 Ep14: Bleicher and Nardello Talk About Finding the Best Fit for Fellowship in Oncology
S6 Ep13: Roychowdhury Relays Impact of Recent Infigratinib Approval in FGFR+ Cholangiocarcinoma
S6 Ep12: Katona Highlights the Hallmarks of Hereditary Diffuse Gastric Cancer
S6 Ep11: Marvels in Medicine: Allison Talks Everything from Advances in Immunotherapy to Jamming With Willie Nelson
S6 Ep10: Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC
S6 Ep9: Ku Reviews Exciting ESMO Data in Gastric/GEJ Cancer
S6 Ep8: Gradishar Gives Insight Into the Growing Role of SERDs in Breast Cancer
S6 Ep7: Tagawa Breaks Down FGFR Testing and the Use of Erdafitinib in Bladder Cancer
S6 Ep6: Yarchoan Talks Research Directions in Fibrolamellar Carcinoma
S6 Ep5: FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory B-ALL
S6 Ep4: Jain and Spaggiari Speak to Surgical and Systemic Considerations for CRC Liver Metastases
S6 Ep3: Johnson Previews the Potential Utility of VS-6766 Plus Defactinib in KRAS+ NSCLC
S6 Ep2: Abid on Optimizing COVID-19 Vaccines in CAR T-Cell Therapy Recipients
S6 Ep1: Ilson Delves Into the Development of Checkpoint Inhibition in Gastric/GEJ Cancers
S5 Ep50: Gordan on Growing the Infrastructure for In-House Genomic Testing
S5 Ep49: DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
S5 Ep48: Moore Voices Excitement With VS-6766 Plus Defactinib in Ovarian Cancer
S5 Ep47: FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
S5 Ep46: Genomically Guided Radiation Dosing in Oncology: Ready for Prime Time?
S5 Ep45: Aggarwal and Girard Analyze Data Amassed With Durvalumab in Unresectable Stage III NSCLC
S5 Ep44: Monk Talks Tisotumab Vedotin and Exciting ESMO Data in Cervical Cancer
S5 Ep43: Dietrich Details Data and Future Research With Immunotherapy in Stage III NSCLC
S5 Ep42: Neel on Maximizing Research Strides in Oncology
S5 Ep41: Loaiza-Bonilla Offers Guidance on Optimizing Treatment Selection in Pancreatic Cancer
S5 Ep40: Lisberg Discusses the Promise of Datapotamab Deruxtecan in Lung Cancer
S5 Ep39: McKay Filters Through Frontline Treatment Considerations in mRCC
S5 Ep38: Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer
S5 Ep37: Sekeres Previews Potential Combination Strategies in HR-MDS
next page